3 hours ago
21
TLDR
- Novo Nordisk stock fell 0.30% to $40.33 despite continued share repurchases.
- Novo Nordisk repurchased 41.7 million B shares worth DKK 11.56 billion.
- The company’s latest buybacks added 1.44 million shares between October 26 and November 2.
- Novo Nordisk accumulated 55.7 million treasury shares, representing 1.2% of capital.
- The pharmaceutical company has used 77.1% of its DKK 15 billion buyback allocation.
Novo Nordisk (NVO) shares declined 0.30% to $40.33, shedding $0.12 during the latest trading session. The decline followed an earlier recovery from session lows, leaving the stock slightly lower. Meanwhile, the pharmaceutical company continued its $15 billion share repurchase programme, bringing total buybacks to 41.7 million shares.
Novo Nordisk Continues Share Buybacks Under DKK 15 Billion Programme
Novo Nordisk continued purchasing its B shares under a repurchase programme launched on February 4, 2026. The programme allows the company to repurchase shares worth up to DKK 15 billion over 12 months. Additionally, the company established a separate execution framework for purchases running from May 6, 2026, through February 1, 2027.
Under this arrangement, Novo Nordisk allocated up to DKK 11.2 billion for B-share repurchases. The company conducts these transactions under European market abuse regulations and applicable safe harbour rules. These provisions establish the regulatory framework governing share repurchases and related market disclosures.
The latest transaction update covers purchases completed between October 26 and November 2, 2026. During this period, Novo Nordisk purchased 240,000 B shares on each reported trading day. The purchases covered October 26, 27, 28, 29, and 30, alongside November 2.
Novo Nordisk Purchases 1.44 Million Shares in Latest Update
The company purchased 1.44 million B shares across the six reported trading sessions. Its average purchase prices ranged from DKK 257.51 to DKK 267.29 per share. Consequently, the transactions added approximately DKK 376 million to the programme’s accumulated purchase value.
Novo Nordisk paid an average of DKK 261.38 per share on October 26. The average price declined to DKK 260.44 on October 27 and DKK 257.51 on October 28. However, the company recorded higher average prices of DKK 258.33 and DKK 265.96 on October 29 and 30.
Purchases continued on November 2 at an average price of DKK 267.29 per share. That transaction represented approximately DKK 64.15 million in total value. Following these purchases, cumulative programme transactions reached 26,955,000 B shares worth DKK 7.76 billion.
Novo Nordisk Treasury Shares Reach 55.7 Million
Novo Nordisk reported holding 55,754,876 B shares as treasury shares following the latest purchases. These holdings represent approximately 1.2% of the company’s total share capital. Meanwhile, the company reported 4.465 billion outstanding A and B shares, including treasury shares.
The broader repurchase programme has recorded substantially higher activity since February 4, 2026. By November 2, Novo Nordisk had purchased 41,714,179 B shares under the overall arrangement. The purchases carried an average price of DKK 277.23 per share.
The total transaction value reached DKK 11,564,364,801 during this period. This amount represents approximately 77.1% of the programme’s DKK 15 billion allocation. Therefore, Novo Nordisk has used a significant portion of its authorised repurchase budget.
The company continues executing the programme within its announced 12-month period. Its latest disclosures provide transaction dates, purchased quantities, average prices, and cumulative values. However, NVO shares still finished the latest session lower despite the ongoing repurchase activity.
The post Novo Nordisk (NVO) Stock: Drops as Company Repurchases 41.7M Shares Under $15B Plan appeared first on Blockonomi.
English (US) ·